Ivonescimab back in tune
China's Harmoni-A trial hits on overall survival, but hopes for a global phase 3 seem optimistic.
Otsuka zips into adjuvant use
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
Bristol takes its bispecific conjugate into lung cancer
A second global pivotal trial will test iza-bren in the same NSCLC setting where patri-dxd failed.
More delays for Regeneron
The company gets another odronextamab knockback, while a key fianlimab readout is postponed.
FDA red and green lights: July 2025
Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.
Bristol pulls ahead of Amgen
The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.
Revolution mortgages royalties for more cash
“We need all the capital we can get our hands on," the company states.
Better late than never for Datroway in lung cancer
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
